Clinical trials: Chordomas
Chordomas, Chondrosarcomas
Proton Radiation for Chordomas and Chondrosarcomas
The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation…
- Trial name
- NCT01449149
- Testing
- Proton Therapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bone Sarcoma, Chondrosarcoma
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects.
- Conditions
- Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone
- Trial name
- NCT05033288
- Testing
- Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Chordoma, Chondrosarcoma
Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose.
- Trial name
- NCT00592748
- Testing
- Charged Particle Radiation Therapy
- Where
- United States
- Volunteers
- 381 people
- Sponsor
- Massachusetts General Hospital
Chordoma
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
This is an open-label, multicenter phase II study to evaluate the safety, efficacy and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with locally advanced or metastatic chordoma.
- Trial name
- NCT06787664
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Chordoma
BN Brachyury and Radiation in Chordoma
The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design.
- Trial name
- NCT03595228
- Testing
- BN-Brachyury plus radiation
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bavarian Nordic
Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body.
- Trial name
- NCT02989636
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Chordoma
Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of…
- Trial name
- CHORDOMES (NCT04486820)
- Testing
- Analysis Immunohistochemical
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Chordoma
Afatinib in Locally Advanced and Metastatic Chordoma
In this phase 2, single arm trial patients with locally advanced or metastatic, pathologically proven, EGFR expressing chordoma will be treated with afatinib.
- Trial name
- NCT03083678
- Testing
- Afatinib
- Where
- 3 sites in Italy, Netherlands and 1 more
- Volunteers
- 43 people
- Sponsor
- Leiden University Medical Center
Soft Tissue Sarcoma, Adult, Ewing Sarcoma
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
IMRiS is a phase II trial which aims to assess the feasibility, efficacy and toxicity of Intensity Modulated Radiotherapy (IMRT) in three different cohorts of patients with primary bone and soft tissue sarcoma and to demonstrate…
- Conditions
- Soft Tissue Sarcoma, Adult, Ewing Sarcoma, Bone Sarcoma, Chordoma
- Trial name
- IMRiS (NCT02520128)
- Testing
- Intensity modulated radiotherapy (IMRT)
- Where
- 28 sites in Ireland, United Kingdom
- Volunteers
- 191 people
- Sponsor
- University College, London
Chordoma
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays.
- Trial name
- NCT00713037
- Testing
- Fluoromisonidazole-PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Chordoma, Locally Advanced Chordoma
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body.
- Conditions
- Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
- Trial name
- NCT03623854
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Chordoma, Tumor
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base
This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment…
- Conditions
- Chordoma, Tumor, Treatment
- Trial name
- HIT-1 (NCT01182779)
- Testing
- Carbon ion, Protons
- Where
- Germany
- Volunteers
- 319 people
- Sponsor
- Heidelberg University